Regeneron Pharmaceuticals, Inc. - REGN
About Gravity Analytica
Recent News
- 03.12.2025 - Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
- 03.11.2025 - Leerink Partners 2025 Global Healthcare Conference
- 03.08.2025 - Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
- 03.04.2025 - TD Cowen 45th Annual Health Care Conference
- 02.28.2025 - Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
- 02.26.2025 - Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
- 02.24.2025 - Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
- 02.18.2025 - Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
- 02.11.2025 - Regeneron Announces Investor Conference Presentations
- 02.11.2025 - Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma